LEUVEN, Belgium, July 17,
2024 /PRNewswire/ -- P95 BV ("P95"), an Ampersand
Capital Partners portfolio company, is proud to announce the
appointment of Laurence De Moerlooze as Chief Medical
Officer (CMO). Laurence will provide medical leadership and
spearhead operational oversight across P95's clinical and
epidemiology activities, driving forward the company's strategic
goals in vaccine innovation and public health.
Laurence brings a wealth of expertise and leadership to P95's
management team, shaped by an impressive career marked by pivotal
positions such as Executive Vice President and Chief Medical
Officer at Bavaria Nordic, and influential senior roles at Takeda
and GSK. After earning a PhD in Virology from the University of
Liège and extensive post-doctoral work in Montreal, London, and Brussels, Laurence amassed over 15 years at
GSK Biologicals. During this time, she was at the forefront of
regulatory affairs, project management, and medical affairs,
playing a significant role in developing vaccines, including one
for HPV. Her subsequent leadership extended to Zika and Norovirus
vaccine development as a Vice President at Takeda, followed by her
4-year tenure as Chief Medical Officer at Bavarian Nordic.
Laurence's unique and vast understanding of vaccine development and
implementation will be a tremendous asset to P95.
Thomas Verstraeten, Chief
Executive Officer of P95 expressed: "I am delighted to
welcome Laurence De Moerlooze to P95. Her visionary leadership and
deep-rooted understanding of all stages of vaccine development and
implementations align perfectly with P95's ambitions as we solidify
our position as a leading global CRO specializing in vaccines and
infectious diseases."
About P95
P95, an Ampersand portfolio company, is a leading global
provider of clinical and epidemiology research solutions with a
specialty focus on vaccines and infectious diseases. With
headquarters in Belgium, offices
across Europe, and regional hubs
in Colombia, South Africa, Thailand, and USA, P95's full-service CRO solutions span
across 5 continents with staff in over 25 countries. P95 offers a
wide range of solutions including phase I-IV clinical studies,
epidemiology, and RWE studies, in addition to scientific and
clinical development consulting, P95 offers end-to-end services
including study start-up, clinical monitoring, sample management,
medical monitoring and pharmacovigilance, qualitative research,
medical writing, data management, biostatistics, and IT.
About Ampersand Capital Partners
Founded in 1988, Ampersand Capital Partners is a middle market
private equity firm with $3 billion
of assets under management dedicated to growth-oriented investments
in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information, visit ampersandcapital.com or
follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/p95-welcomes-laurence-de-moerlooze-as-chief-medical-officer-to-oversee-clinical-and-epidemiology-operations-302198431.html
SOURCE P95 BV